Contact Us
Drug Search Results
More Filters [+]

Pilaralisib

Alternative Names: pilaralisib, xl147, xl-147, xl 147, sar-245408, sar245408, sar 245408
Latest Update: 2022-02-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: PI3K Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Pilaralisib

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Breast Cancer|Oncology Unspecified|Endometrial Cancer

Phase 1: Oncology Solid Tumor Unspecified|Non-Small-Cell Lung Cancer|Ovarian Cancer|Endometrial Cancer|Lymphoma|Breast Cancer|Glioblastoma|Astrocytoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
2011-006140-78

P2

Completed

Oncology Unspecified

2018-05-23

TED12414

P2

Completed

Oncology Unspecified

2018-05-23

TED12863

P1

Completed

Lymphoma

2015-02-01

TCD11721

P1

Completed

Oncology Solid Tumor Unspecified

2014-05-01

Recent News Events

Date

Type

Title

02/01/2022

PubMed

 Translating in vitro CFTR rescue into small molecule correctors for cystic fibrosis using the Library of Integrated Network-based Cellular Signatures drug discovery platform.

10/08/2020

PubMed

 Screening and Reverse-Engineering of Estrogen Receptor Ligands as Potent Pan-Filovirus Inhibitors.

08/01/2020

PubMed

 The PI3K/mTOR dual inhibitor GSK458 potently impedes ovarian cancer tumorigenesis and metastasis.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions